A class of drugs that has lived overwhelmingly in rare disease is now aiming at some of the largest cardiovascular markets there are.
The science mostly holds. What is unproven is whether the effect sizes justify the move and whether anyone will pay for it at scale, and the first real answer arrives this year.
Built For Scarcity
Of the 24 RNA and DNA therapeutics the FDA has approved, 21 treat conditions the Orphanet ontology classifies as rare, fewer than one in 2,000 people. That was never accidental. Small populations let a developer prove a concept in a manageable trial, price against little competition, and reach the market through accelerated pathways built on biomarker endpoints. The whole model was tuned for scarcity.
The pipeline no longer resembles the approved list. Norstella's Pharmaprojects counts more than 30 nucleic acid therapeutics in clinical development for cardiovascular or cardiometabolic disease, among them hypertension, atherosclerotic cardiovascular disease, and dyslipidemia, none of them rare. Cardiovascular is now the second-largest grouping after oncology, whose lead is inflated by how many indications its candidates span.
What made the jump possible is a delivery trick. Bolting a sugar, N-acetylgalactosamine or GalNAc, onto an oligonucleotide steers it to liver cells, so a single injection under the skin can switch off a target gene in the liver. First used in rare metabolic disease, GalNAc conjugation has become the default way to reach the liver-made proteins that drive cardiovascular risk. Little of the rest works without it.